Log In
BCIQ
Print this Print this
 

Idylla NRAS-BRAF-EGFR S492R Mutation Assay

  Manage Alerts
Collapse Summary General Information
Company Biocartis Group N.V.
DescriptionIn vitro diagnostic test that detects 25 mutations in the NRAS, BRAF and EGFR oncogenes directly from formalin-fixed paraffin-embedded (FFPE) tissue sections in about 2 hours
Molecular Target
Mechanism of Action 
Therapeutic ModalityDiagnostics: Biomarkers and companion diagnostics
Latest Stage of DevelopmentMarketed
Standard IndicationCancer, Diagnostic
Indication DetailsDectect NRAS, BRAF and EGFR mutations in metastatic colorectal cancer
Regulatory Designation
PartnerAmgen Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

02/03/2016

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today